This page contains brief information about dexrazoxane hydrochloride and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Use in Cancer
Dexrazoxane hydrochloride is approved to treat severe side effects caused by certain types of chemotherapy. It is used to treat the following:
- Cardiac (heart) side effects caused by doxorubicin in women being treated for metastatic breast cancer. Dexrazoxane hydrochloride helps make the side effects happen less often and makes them less severe when they do occur. It is used only in women who have already received high doses of doxorubicin and continue to be treated with it. This use is approved for the Zinecard brand of dexrazoxane hydrochloride.
- Extravasation caused by intravenous anthracyclines. Extravasation occurs when injected drugs leak out of the vein, into surrounding tissue. This can cause redness, pain, and swelling, and may damage the tissue. This use is approved for the Totect brand of dexrazoxane hydrochloride.
More About Dexrazoxane Hydrochloride
Definition from the TCH Drug Dictionary – Detailed scientific definition and other names for this drug.
MedlinePlus Information on Dexrazoxane Hydrochloride – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Clinical Trials Accepting Patients
Find Clinical Trials for Dexrazoxane Hydrochloride – Check for trials from TCH’s list of cancer clinical trials now accepting patients.